Richard Sachse joins Anaveon as CMO

Swiss immune-oncology specialist Anaveon has appointed Richard Sachse as its chief medical officer (CMO) effective February 1, 2025.

Dr Sachse brings more than 25 years of experience in the biopharma industry as a physician and scientist. Dr Sachse will succeed Dr Eduard Gasal, will be leaving Anaveon to explore a new opportunity.

Dr Sachse will be joining Anaveon from SOTIO Biotech where he serves as CMO. With more than 25 years of experience as a physician and scientist, he has extensive expertise in pharmaceutical development covering the entire value chain from pre-clinical to registration. In addition to registration studies, he is especially experienced in the design and implementation of translational programs to bridge research programs to the clinic. Prior to joining SOTIO, he led the medical, scientific, regulatory and pharmacovigilance activities as chief scientific officer at Neovii. As SCO and CMO at Aeterna Zentaris, he was successful in achieving Food and Drug Administration (FDA) approval of Macimorelin. This was preceded by steady growth through several managerial career steps at Bayer (BAYN: DE), Peptor, Schwarz Pharma, UCB (Euronext: UCB) and Boehringer Ingelheim.